New combo therapy aims to tackle tough lung cancer
NCT ID NCT07175220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether combining the experimental drug SHR2554 with other anti-tumor treatments can safely shrink tumors in people with advanced non-small cell lung cancer that cannot be removed by surgery. About 200 participants will receive one of three drug combinations over 21-day cycles. The study focuses on safety and how well the tumors respond, with the hope of finding a new treatment option for this serious disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR2554 tablets combined with other anti-tumor drugs (SHR-A2102, Adabelimumab, or SHR-1701)
- What this could lead to
- If successful, this could point toward a new combination treatment option for people with advanced non-small cell lung cancer that is not curable but may help control the disease.
- What could go wrong
- This is an early-phase (Phase 2) trial with only 200 participants, so results may not apply to everyone. The combinations may cause side effects or fail to shrink tumors as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pfizer drug takes on Hard-to-Treat cancers
- New pill hopes to shrink lung tumors in early trial
- New targeted therapy aims to outshine standard chemo for HER2-mutant lung cancer
- New drug cocktail aims to shrink lung tumors
- New drug cocktail hopes to tackle tough lung cancer
- New pill HRS-4508 targets tough lung cancers